Among older women (aged ≥50 years) with ERBB2 (formerly HER2 or HER2/neu)–positive breast cancer, research has shown racial and ethnic disparities in access to ERBB2-targeted therapies, with Black women receiving treatment at lower rates than their White counterparts. Here, ERBB2 is linked to breast cancer.